Sarlis Nicholas J. 4
4 · SELLAS Life Sciences Group, Inc. · Filed Mar 18, 2019
Insider Transaction Report
Form 4
Sarlis Nicholas J.
Chief Medical Officer and SVP
Transactions
- Award
Stock Option (Right to Buy)
2019-03-14+50,000→ 50,000 totalExercise: $1.38Exp: 2019-12-31→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]All of the option shares will vest and become exercisable upon the closing of a Change of Control transaction (as defined in Mr. Sarlis' stock option grant notice), provided that the Reporting Person remains in continuous service with the Issuer on the vesting date.